Evaluation of cccDNA and Total HBV DNA Kinetics in Lymphocytes, Total Blood and Serum in Chronic Hepatitis B Patients Treated With Adefovir Dipivoxil and Peg Interferon Alpha 2a (DNA-EVAL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00199732|
Recruitment Status : Completed
First Posted : September 20, 2005
Last Update Posted : April 17, 2013
Serum HBV DNA is a referent but insufficient marker of therapeutic follow-up in chronic hepatitis B treatment. Intra hepatic cccDNA disappearance reflects HBV eradication in the liver.
Intra lymphocyte cccDNA could be a new marker of HBV eradication after treatment.
The major interest of this marker is that it can be measured by a simple blood test instead of a liver biopsy.
|Condition or disease|
|Chronic Hepatitis B|
- Studying intra lymphocyte and blood cccDNA: before inclusions, D0 then each month during the first three months each three months during treatment and follow-up.
- Viral kinetics:Before inclusions, at D0, then monthly till the end of treatment and follow-up: Evolution of quantitative viraemia in serum Evolution of quantitative viraemia in circulating lymphocytes Evolution of quantitative viraemia in total blood
- Studying viral genotypes
|Study Type :||Observational|
|Actual Enrollment :||19 participants|
|Official Title:||Evaluation of cccDNA and Total HBV DNA Kinetics in Lymphocytes, Total Blood and Serum in Chronic Hepatitis B Patients Treated With Adefovir Dipivoxil and Peg Interferon Alpha 2a|
|Study Start Date :||December 2004|
|Actual Primary Completion Date :||July 2009|
|Actual Study Completion Date :||July 2009|
- Kinetic cccDNA [ Time Frame: 6 months ]Studying the kinetics of cccDNA in cells and whole blood
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00199732
|Service de Médecine Interne|
|Service de Virologie|
|Service des Maladies Infectieuses et Tropicales|
|Principal Investigator:||Véronique Loustaud-Ratti, MD||University Hospital, Limoges|